Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned an average rating of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $8.50.

A number of equities research analysts have issued reports on the stock. Roth Mkm reiterated a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gain Therapeutics in a research note on Friday, April 10th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th.

Institutional Investors Weigh In On Gain Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sprott Inc. bought a new stake in shares of Gain Therapeutics during the 4th quarter valued at approximately $39,000. Commonwealth Equity Services LLC acquired a new stake in Gain Therapeutics during the 4th quarter worth approximately $41,000. Millennium Management LLC acquired a new stake in Gain Therapeutics during the 4th quarter worth approximately $45,000. Engineers Gate Manager LP acquired a new stake in Gain Therapeutics during the 4th quarter worth approximately $47,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in Gain Therapeutics during the 3rd quarter worth approximately $28,000. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Price Performance

NASDAQ:GANX opened at $1.70 on Monday. Gain Therapeutics has a 52 week low of $1.41 and a 52 week high of $4.34. The firm has a market cap of $72.51 million, a price-to-earnings ratio of -2.93 and a beta of 0.16. The firm’s 50-day simple moving average is $1.86 and its 200 day simple moving average is $2.34. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.69 and a current ratio of 4.69.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). During the same quarter in the prior year, the business earned ($0.16) EPS. As a group, sell-side analysts predict that Gain Therapeutics will post -0.54 earnings per share for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.